Vivani Medical (VANI) EBITDA Margin (2014 - 2022)

Vivani Medical has reported EBITDA Margin for 9 years, with the latest figure at 244.19% in Q1 2022.

• On a quarterly basis, EBITDA Margin fell 6650.0% year-over-year to 244.19% in Q1 2022; TTM through Jun 2022 was 797.33%, a 54686.0% decrease from a year earlier, with the FY2019 full-year figure at 1004.85%, down 49500.0% from the prior year.
• EBITDA Margin was 244.19% for Q1 2022 at Vivani Medical, up from 217812.5% in the prior quarter.
• The five-year high for EBITDA Margin was 100.12% in Q3 2020, with the low at 217812.5% in Q3 2021.
• Average EBITDA Margin over 5 years is 17382.1%, with a median of 556.5% recorded in 2020.
• The sharpest annual moves came in 2020 and 2021: EBITDA Margin soared 151407 bps in 2020, then plunged 21771238 bps in 2021.
• Over 5 years, EBITDA Margin stood at 502.38% in 2018, then sank by 225 bps to 1635.01% in 2019, then surged by 94 bps to 100.12% in 2020, then tumbled by 217441 bps to 217812.5% in 2021, then surged by 100 bps to 244.19% in 2022.
• The last three EBITDA Margin figures came in at 244.19% (Q1 2022), 217812.5% (Q3 2021), and 177.69% (Q1 2021), per Business Quant data.